The Alopecia Areata market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alopecia Areata: An Overview
According to the National Alopecia Areata Foundation, Alopecia Areata (AA) is a common autoimmune skin disease, which causes hair loss on the scalp, face, and at times on other areas of the body. The affected hair follicles are attacked by a person’s immune system (white blood cells), which results in the seizing of the hair growth stage. Hair follicles remain alive, and hair can regrow at any time in Alopecia Areata.
Alopecia Areata usually begins with one or more patches which may be small, round, smooth on the scalp that can progress to total scalp hair loss or complete body hair loss. Genetic predisposition and environmental factors increase the chances of developing Alopecia Areata.
Alopecia Areata Market Key Facts
-
According to Chantal Bolduc et al., 2018, the prevalence of alopecia areata (AA) in the general population is estimated to be 0.1–0.2%. The lifetime risk of developing alopecia areata is estimated to be 1.7%. All races are affected equally by alopecia areata and no increase in prevalence has been found in a particular ethnic group.
-
As per the National Organization of Rare Disease, alopecia areata is most common among children and approximately 2.5 million people are suffering from alopecia areata in the United States.
-
As per Herbert Pratt et al. 2017, alopecia areata affects approximately two percent of the general population at some point during their lifetime
Get FREE sample copy @ Alopecia Areata Therapeutics Market
Key Benefits of Alopecia Areata Market Report
-
The report provides an in-depth analysis of Alopecia Areata Market Size and Share till 2030 in the seven major markets.
-
The report will help in developing business strategies by understanding the Alopecia Areata Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.
-
It covers Alopecia Areata current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
-
The report provides a detailed assessment of the Alopecia Areata market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Currently, there is no cure and no FDA-approved treatments for alopecia. The alopecia areata (AA) is the most common form of alopecia and is characterized by patchy scalp baldness. The potential for hair recovery is maintained but, at present, there is no treatment able to induce a permanent remission of this disease or approved to treat it. Thus, the market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of treatment options available. The main goal of treatment is to block the immune system attack or stimulate the regrowth of hair. This can be effective, especially for people with milder forms of the disease.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Alopecia Areata market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Alopecia Areata market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Alopecia Areata Epidemiology Forecast
The epidemiology section covers insights about the historical and current Alopecia Areata patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Alopecia Areata Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched in the market during the study period. The analysis covers Alopecia Areata market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Alopecia Areata Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
The dynamics of the Alopecia Areata market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.
Some of the key companies in the Alopecia Areata Market include:
-
Pfizer
-
Suzhou Zelgen Biopharmaceuticals
-
Eli Lilly and Company
-
Incyte Corporation
-
Legacy Healthcare
-
Concert Pharmaceuticals
-
Alcaris Therapeutics Inc.
And many others.
Alopecia Areata Therapies covered in the report include:
-
PF-06651600
-
Jaktinib
-
Baricitinib
-
ATI-502
-
LH-8
-
CTP-543
And many others.
Request for Sample @ Alopecia Areata Emerging Therapies and Key Companies
Table of Content
1. Key Insights
2. Executive Summary
3. Alopecia Areata Competitive Intelligence Analysis
4. Alopecia Areata Market Overview at a Glance
5. Alopecia Areata Disease Background and Overview
6. Alopecia Areata Patient Journey
7. Alopecia Areata Epidemiology and Patient Population
8. Alopecia Areata Treatment Algorithm, Current Treatment, and Medical Practices
9. Alopecia Areata Unmet Needs
10. Key Endpoints of Alopecia Areata Treatment
11. Alopecia Areata Marketed Products
12. Alopecia Areata Emerging Therapies
13. Alopecia Areata Seven Major Market Analysis
14. Attribute Analysis
15. Alopecia Areata Market Outlook (7 major markets)
16. Alopecia Areata Access and Reimbursement Overview
17. KOL Views on the Alopecia Areata Market.
18. Alopecia Areata Market Drivers
19. Alopecia Areata Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/alopecia-areata-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/